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Conclusions. These results suggest that in secondary hyper-Expression of PRAD1/cyclin D1, retinoblastoma gene prod-
plasia caused by uremia, at least remarkable overexpressionucts, and Ki67 in parathyroid hyperplasia caused by chronic
of PRAD1/cyclin D1 induced by PTH gene rearrangement mayrenal failure versus primary adenoma.
be not the major genetic abnormality responsible for tumori-Background. In primary hyperparathyroidism, certain ge-
genesis. Heterogenous genetic changes seem to contribute tonetic abnormalities responsible for parathyroid tumorigenesis
are proposed, and it has been reported that the overexpression monoclonal proliferation of parathyroid cells induced by the
of PRAD1/cyclin D1 induced by a DNA rearrangement of expression of PRAD1/cyclin D1 or by some other mechanism
the parathyroid hormone (PTH) gene is one of the genetic independent of the amplification of the proto-oncogene.
disorders in a number of primary parathyroid adenomas. How-
ever, in secondary hyperparathyroidism caused by uremia, the
mechanism of monoclonal proliferation in nodular parathyroid
It has been suggested that a number of pathogenetichyperplasia is not well understood. To elucidate the mecha-
nism, we examined the expression of PRAD1/cyclin D1, retino- factors may contribute to secondary hyperparathyroid-
blastoma gene products, and Ki67 in primary adenoma and ism caused by chronic renal failure, for example, hypocal-
secondary hyperplasia. cemia, phosphate retention, active vitamin D deficiency,
Methods. In adenomas (N 5 15) and associated glands (N 5
reduction of vitamin D receptors (VDRs), and reduction7) with normal histology obtained from patients with primary
of Ca21-sensing receptors [1–3]. However, neither thehyperparathyroidism and in diffuse (N 5 14), multinodular
(N 5 58), and single nodular (N 5 28) glands from patients who mechanism regulating the number of parathyroid cells
underwent parathyroidectomy for renal hyperparathyroidism, nor the process of hyperplasia is completely understood.
the expression of these cell cycle regulators was evaluated by
Histopathological studies have shown that the character-immunohistochemical technique. A labeling index was used to
istic findings of renal hyperparathyroidism can be sum-define the proportion of cells with positive nuclear staining by
each antibody. marized as asymmetric enlargement, nodularity, and an
Results. In 6 out of 15 (40%) primary adenomas, PRAD1/ increase in oxyphilic/transitional oxyphilic cells. Histo-
cyclin D1 was overexpressed (a labeling index of more than pathologically, parathyroid hyperplasia induced by renal500), possibly because of the PTH gene rearrangement, but
insufficiency is mainly divided into diffuse and nodularnot in secondary hyperplasia, including single nodular glands.
Compared with diffuse hyperplasia, nodular hyperplasia showed types. In diffuse hyperplastic glands, the number of pa-
a significantly higher expression of PRAD1/cyclin D1 (P , renchymal cells diffusely increase with normal lobular
0.05), retinoblastoma gene products (P , 0.05), and Ki67 (P , structures, and fat cells usually coexist in the glands.0.05). However, no statistically significant correlation between
Nodular hyperplasias are recognized in glands exhibitingthe expression of PRAD1/cyclin D1 and that of Ki67 was ob-
at least one well-circumscribed, encapsulated noduleserved in both primary adenoma and secondary hyperplasia.
with virtually fat cell-free accumulation of parenchymal
cells. In nodular hyperplasias, the glands usually haveKey words: parathyroid adenoma, secondary hyperparathyroidism, tu-
morigenesis, uremia, nodular hyperplasia. several nodules, and each nodule usually consists of a
single cell type (multinodular gland). Sometimes one
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Table 1. Number of specimens examined showing therounding parathyroid tissue. This type of nodular hyper-
mean glandular weights
plasia is called a single nodular gland [4, 5]. Sometimes
Glandular weightit is difficult to differentiate a single nodular gland from
Pathological diagnosis No. of specimens mg
adenoma in primary hyperparathyroidism by only the
Primary hyperparathyroidismhistopathological findings. Associated (normal) gland 7 49.4 626.9
Adenoma 15 1538.361650.2Based on investigations of the relationship between
Secondary hyperparathyroidismglandular weight and the pattern of hyperplasia, it is
due to uremia
obvious that as the gland becomes heavier, the pattern Diffuse hyperplasia 14 268.26211.0
Nodules of multi-nodular 58 782.5 6479.0changes from diffuse to nodular hyperplasia [4, 5]. Image
hyperplasia
cytometric DNA analyses have indicated that the cells Single nodular gland 21 2458.4 61228.1
in nodules of nodular hyperplasia have a greater growth
potential than the surrounding parenchymal cells [6]. In
a recent study, by clonal analysis using random inactiva-
Table 2. Patient profile for those with hyperparathyroidism (HPT)tion of the X-chromosome–linked gene we found that
Primary HPT Secondary HPTdiffuse hyperplasia proliferates polyclonally, whereas
No. of cases 15 33nodules of nodular hyperplasia grow monoclonally [7].
Age years 52.3612.5 46.768.5In 1995, Arnold et al reported that 64% of patients who
Total serum calcium mEq/liter
had undergone parathyroidectomy for advanced renal (normal range 4.1–5.4) 6.0 60.6 5.160.4
Serum phosphate mg/dlhyperparathyroidism had at least one monoclonal para-
(normal range 2.5–4.3) 2.4 60.5 6.261.6thyroid gland [8]. Based on our histopathological and Intact PTH pg/ml
(normal range 15–60) 226.4 6172.3 1060.66530.6clonal investigation, we hypothesize that, in renal hyper-
PTH is parathyroid hormone.parathyroidism, parathyroid glands initially proliferate
diffusely and polyclonally because of some pathogenetic
factors. Then the glands are transformed to nodular hy-
perplasia, with one or several monoclonal nodules possi- METHODS
bly being induced by some kind of genetic abnormality.
Our operative indications and operative strategy for
In sporadic primary hyperparathyroidism, certain ge- renal hyperparathyroidism have been described recently
netic abnormalities are proposed [9]. For instance, Ar- [15]. Specimens from 33 patients who underwent para-
nold et al reported two parathyroid adenomas in 43 pa- thyroidectomy for renal hyperparathyroidism and 15
tients, revealing rearrangement involving the parathyroid with histologically typical primary parathyroid adenomas
hormone (PTH) locus [10, 11]. These genes encode a were used for our immunohistochemical studies. In the
cyclin, parathyroid adenomatosis 1 (PRAD1), called cy- 15 cases of primary hyperparathyroidism, seven associ-
clin D1, which may play an important role in controlling ated parathyroid glands removed concomitantly for his-
the cell cycle [12, 13]. It is reported that PRAD1/cyclin topathological diagnosis were also examined. All of the
D1 combines with cyclin-dependent kinase and phos- associated glands showed normal histopathology. In the
33 cases of renal hyperparathyroidism, the materials in-phorylates retinoblastoma gene products (pRB) to in-
cluded 14 glands with diffuse hyperplasia and 58 nodulesduce the G1-S transition [14]. It is suggested that this
from 28 multinodular hyperplastic glands. Moreover, 21overexpression of PRAD1/cyclin D1 is one of the genetic
single nodular glands were examined. The mean glandu-abnormalities responsible for tumorigenesis in sporadic
lar weight is shown in Table 1. Sex ratio, mean age, meanprimary parathyroid adenomas.
levels of total serum calcium, serum phosphate, and in-In secondary hyperparathyroidism caused by renal
tact PTH measured with an Allegro kit (normal rangefailure, the mechanism of monoclonal proliferation is
of less than 60 pg/ml) are shown in Table 2. All cases innot well understood. To elucidate the mechanisms of para-
both primary and secondary hyperparathyroidism re-
thyroid hyperplasia in renal hyperparathyroidism, an im-
vealed definitive clinical hyperparathyroidism.
munohistochemical technique was used to examine the All specimens were fixed in 10% formalin and were
expression of PRAD1/cyclin D1, pRB, and Ki67, a nu- routinely processed to paraffin. Serial sections (3 mm
clear antigen associated with all phases of the cell cycle thick) were cut and mounted on aminopropyltriethoxysi-
except G0 and one of the markers representing cell- lane-coated glass slides. These sections were deparaffin-
growth potential in hyperplastic glands removed from ized in xylene and were rehydrated through an ethanol
patients with advanced renal hyperparathyroidism. Com- series. The sections were then placed in jars containing
parisons were made with the expressions of these gene phosphate-buffered saline and heated in an autoclave
(1218C, two atoms) for 10 minutes prior to using theproducts in primary adenomas.
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primary antibody. The sections were pretreated with The results of the LI of PRAD1/cyclin D1 are shown
in Figure 5. Scarcely any associated glands contained10% normal goat serum at 48C for 10 minutes to block
nonspecific binding of the primary antibodies. The sec- PRAD1/cyclin D1 immunoreactive cells. The mean
value 6 se of the LI in these glands was 0.7 6 1.9 (rangetions were then incubated overnight at 48C with the pri-
mary antibody. The following primary antibodies were 0 to 5). PRAD1/cyclin D1 was expressed significantly
more often in primary adenoma (P , 0.005), diffuseused: anti-PRAD1/cyclin D1 gene products (clone 5D4)
[16], antihuman pRB (clone 3H9, dilution 1:50; both hyperplasia (P , 0.05), multinodular hyperplasia (P ,
0.001), and single nodules (P , 0.005) in secondary hy-from Medical and Biological Laboratories Co. Ltd., Na-
goya, Japan), and anti-Ki67 (MIB-I; dilution 1:100; Im- perplasia than in associated glands. Primary adenomas
were clearly divided into two groups according to themunotech S.A., Marseille, France). Immunostaining was
performed with the biotin-streptavidin complex (ABC), expression of PRAD1/cyclin D1. In 6 out of 15 (40%)
adenomas, the LI of PRAD1/cyclin D1 exceeded 500,diaminobenzedine as chromogen. The ABC kit was from
Nichirei (Tokyo, Japan). Hematoxylin was used as the whereas the minimum LI of these glands was 545. How-
ever, in the other nine adenomas, the LI was less thancounterstain. The positive control consisted of a mantle
cell lymphoma known to overexpress PRAD1/cyclin D1, 60. Parathyroid glands in secondary hyperplasia were
not distinctly divided into the two groups, in the sameand negative controls consisted of the parathyroid tissue
with mouse immunoglobulin substituted for primary an- way as primary adenomas, by expression of PRAD1/
cyclin D1. Maximum LI in secondary hyperplasia wastibodies. Only distinct nuclear immunoreactivity to
PRAD1/cyclin D1, pRB, and Ki67, respectively, was 430, and no gland with a LI of PRAD1/cyclin D1 more
than 500 was detected. The mean LI value 6 se wasdeemed positive. Immunoreactive cells were counted in
randomly selected areas on each specimen, and the label- 2.1 6 4.3 (range 0 to 16) for diffuse hyperplasia, 50.8 6
106.3 (0 to 430) for nodules of multinodular hyperplasia,ing index (LI) was calculated as the number of positive
and 61.2 6 96.2 (0 to 380) for single nodular glands.immunoreactive nuclei per 1000 parenchymal cells.
In multinodular hyperplasia and single nodular glands,
Statistical analysis PRAD1/cyclin D1 was expressed significantly more of-
ten than in diffuse hyperplasia (P , 0.05).All the data were expressed as mean 6 se. Statistics
The results of pRB expression are illustrated in Figurewere analyzed with Tukey’s nonparametric analysis. P
6. The mean 6 se and the range of LI for each specimenvalues of less than 0.05 were considered significant.
were 0.3 6 0.5 (range 0 to 1) for the associated glands,
24.7 6 37.9 (0 to 150) for primary adenomas, 4.7 6 5.0
RESULTS (1 to 16) for diffuse hyperplasia, 17.4 6 18.2 (1 to 100)
Figure 1 shows the results of immunohistostaining in for multinodular hyperplasia, and 26.0 6 26.9 (1 to 132)
associated (normal) glands when using anti-Ki67, anti- for single nodular glands. In adenomas (P , 0.005), diffuse
PRAD1/cyclin D1, and anti-pRB antibodies. In almost hyperplasia (P , 0.05), multinodular hyperplasia (P ,
all cells, the nuclei were not stained by these antibodies. 0.001), and single nodular glands (P , 0.005), pRB was
Primary adenomas (Fig. 2) and secondary hyperplasia expressed significantly more often than in associated
(Fig. 3) contained some cells in which the nuclei were glands. Similar to Ki67, PRAD1/cyclin D1, in multinodular
stained by anti-Ki67, anti-PRAD1/cyclin D1, and anti- and single nodular glands, pRB was expressed signifi-
pRB antibodies. In positive cells, only the nuclei were cantly more often than in diffuse hyperplasia (P , 0.05).
stained diffusely because these proteins mainly exist in A comparison of the expression of Ki67, PRAD1/
nuclei. The immunostaining patterns using each antibody cyclin D1, and pRB in diffuse versus nodular hyperplasia
did not differ between primary adenoma and secondary demonstrated that the expression of all three markers
hyperplasia (Figs. 2 and 3). was significantly higher in nodular hyperplasia than in
The mean 6 se and range of LI of Ki67 were 0.6 6 diffuse hyperplasia (P , 0.05; Figs. 4, 5 and 6).
1.2 (range 0 to 3) in associated glands, 11.1 6 8.6 (1 to In primary adenomas, neither those with nor without
30) in primary adenomas, 5.1 6 3.3 (1 to 10) in diffuse overexpression of PRAD1/cyclin D1 showed any rela-
hyperplasia, 17.9 6 16.0 (1 to 86) in multinodular hyper- tionship between the expression of Ki67, pRB, the glan-
plasia, and 16.5 6 10.5 (2 to 32) in single nodular glands. dular weight, serum calcium level, PTH level, or clinical
Ki67 was expressed significantly more often in primary manifestations of hyperparathyroidism. A comparison
adenomas (P , 0.005), diffuse hyperplasia (P , 0.05), of the expression of PRAD1/cyclin D1 and Ki67 revealed
multinodular hyperplasia (P , 0.001), and single nodules no statistically significant correlation both in primary
(P , 0.005) in secondary hyperplasia than in the associ- adenoma and secondary nodular hyperplasia, including
ated glands. In multinodular hyperplasia and single nodu- single nodular glands. In some primary adenomas and
lar glands, Ki67 stained significantly more frequently than secondary hyperplasia, Ki67 was overexpressed indepen-
dent of the expression of PRAD1/cyclin D1 (Fig. 7).in the diffusely hyperplastic glands (P , 0.05; Fig. 4).
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Fig. 1. Immunohistochemical findings regarding Ki67 (A), PRAD1/cyclin D1 (B), and retinoblastoma gene products (pRB; C) in associated (normal)
parathyroid gland. In almost all parathyroid parenchymal cells, the nuclei were not stained. Labeling index (LI): Ki67, 3; PRAD1/cyclin D1, 0; pRB, 1.
Fig. 2. Immunohistochemical findings regarding Ki67 (A), PRAD1/cyclin D1 (B), and pRB (C) in parathyroid adenoma in primary hyperparathy-
roidism. Only nuclei were stained by each monoclonal antibody. LI: Ki67, 7; PRAD1/cyclin D1, 797; pRB 150.
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Fig. 3. Immunohistochemical findings regarding Ki67 (A), PRAD1/cyclin D1 (B), and pRB (C) in nodular parathyroid hyperplasia caused by
chronic renal failure. The immunostaining patterns using each antibody did not differ between primary adenoma and secondary hyperplasia. LI:
Ki67, 26; PRAD1/cyclin D1, 210; pRB, 44.
Fig. 4. Results of the immunohistochemical
study of Ki67. Ki67 in primary adenoma (P ,
0.005), diffuse hyperplasia (P , 0.05), nodular
hyperplasia (P , 0.001), and single multinodu-
lar gland (P , 0.005) stained significantly
more frequently than in normal (associated)
glands and was expressed significantly more
often in multinodular and single nodular
glands (P , 0.05) than in diffuse hyperplasia.
DISCUSSION roid adenoma subset contains a clonal chromosome 11
inversion. This DNA rearrangement was discovered inIn sporadic primary hyperparathyroidism, the overex-
a molecular study of the PTH gene structure. Regardingpression of PRAD1/cyclic D1 induced by the PTH gene
molecular oncological principles, a proto-oncogene wasrearrangement has been suggested to be one of the major
suggested to lie adjacent to the chromosome breakpoint.gene abnormalities in parathyroid tumorigenesis, just as
in some kinds of malignant tumors [17–22]. The parathy- Subsequent cloning of this breakpoint-adjacent DNA
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Fig. 5. Results of the immunohistochemical
study of PRAD1/cyclin D1. In 6 out of 15
(40%) primary adenomas, PRAD1/cyclin D1
was remarkably overexpressed (LI . 500). In
nine adenomas, the LI of PRAD1/cyclin D1
was less than 60 and was not overexpressed.
In both diffuse and nodular hyperplasia, in-
cluding single nodular glands of secondary hy-
perparathyroidism, the LI of PRAD1/cyclin
D1 was less than 500. In multinodular hyper-
plasia and single nodular glands, PRAD1/
cyclin D1 was expressed significantly more of-
ten than in diffuse hyperplasia (P , 0.05).
Fig. 6. Results of the immunohistochemical
study of pRB. In primary adenoma (P ,
0.005), diffuse hyperplasia (P , 0.05), multi-
nodular hyperplasia (P , 0.001), and single
nodular gland (P , 0.005), pRB stained sig-
nificantly more often than in normal (associ-
ated) glands. In nodular hyperplasia, including
single nodular glands, pRB was expressed sig-
nificantly more often than in diffuse hyperpla-
sia (P , 0.05).
led to the identification of a previously unknown gene, noreactivity of greater than 20% of the tumor cells. They
reported that seven of these 12 adenomas showed strongwhich was called PRAD1 [10]. Cloning of the full-length
PRAD1 cDNA revealed that the encoded protein is 295 staining of 50 to 70% of the cells, which is equivalent to
an adenoma with a proven PTH-cyclin D1 gene re-amino acids in length. PRAD1 is also known as cyclin
D1 [12, 13]. The known involvement of cyclins in the arrangement [23]. In our series, in 6 of 15 parathyroid
adenomas (40%), the nuclei were stained in more thancell cycle control apparatus immediately suggested the
possible participation of PRAD1/cyclin D1 in neoplastic half of the tumor cells by PRAD1/cyclin D1 monoclonal
antibody. Primary adenomas proved to be very distinctlyparathyroid cell growth as well as in normal growth. This
PTH/PRAD1 rearrangement has been identified in only divided into two groups by the expression of PRAD1/
cyclin D1. In one group, the nuclei of more than half oftwo patients with symptomatic non-MEN1 hyperpara-
thyroidism caused by large adenomas [10]. In an immu- the tumor cells stained positively, whereas in the other
group, fewer than 6% of the cells were stained. In ournohistochemical study, Hsi et al recently found that when
using polyclonal antibodies specific for PRAD1/cyclin series, we could not find specimens of primary adenomas
for which the LI of PRAD1/cyclin D1 was 20 to 50%.D1, 12 of 65 adenomas (18%) stained positively for the
PRAD1/cyclin D1, as evidenced by strong nuclear immu- Although the antibody to PRAD1/cyclin D1 we used
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Fig. 7. Correlation between the expression of
PRAD1/cyclin D1 and that of Ki67 in multi-
nodular, single nodular glands, and primary
adenoma. No significant correlation between
the two parameters was detected. In six adeno-
mas, PRAD1/cyclin D1 was remarkably over-
expressed (LI . 500), but expression of Ki67
was not remarkably high. In some adenomas
and nodular hyperplasia, including single nod-
ular glands, the LI of PRAD1/cyclin D1 was
less than 10, but that of LI of Ki67 exceeded
10. It is speculated that heterogenous genetic
abnormality may contribute to parathyroid tu-
morigenesis. Symbols are: (3) primary ade-
noma (N 5 15); (d) multinodular (N 5 58)
glands; (n) single nodular glands (N 5 28) in
secondary hyperparathyroidism.
was different from the antibody that Hsi et al used, when malignant tumor. It is suspected that those adenomas
without overexpression of PRAD1/cyclin D1 may bemore than half of the tumor cells are strongly stained
by these PRAD1/cyclin D1 antibodies, it is strongly sug- induced by a different mechanism such as a loss of MEN1
suppressor genes [26–29] or the loss of novel tumor sup-gested that the tumors are growing by overexpression of
PRAD1/cyclin D1 induced by PTH gene rearrangement. pressor gene, as has been speculated by some researchers
[29–31]. They found in occasional parathyroid adenomasThere is a discrepancy between the frequency of DNA
rearrangement reported by Arnold et al and this expres- that there was a frequent loss of heterozygosity on chro-
mosome 1p, 6q, 11p, 11q, and 15q.sion of cyclin D1 protein detected by immunohistochem-
ical technique [10, 23]. Hsi et al speculated that this The following three findings led us to speculate that
when the nuclei of more than 50% of the parathyroiddiscrepancy might be caused by an undetectable DNA
rearrangement. They found breakpoints more than 200 cells are stained by antibodies for PRAD1/cyclin D1,
parathyroid gland growth may be induced by PTH genekilobases distant from the cyclin D1 gene [23]. Similar
widely varying PRAD1/cyclin D1 breakpoint locations rearrangement. (a) Hsi et al found that in parathyroid
adenoma with a proven PTH-cyclin D1 gene rearrange-have been found in mantle cell lymphomas [24], and a
similar phenomenon has also been reported in other ment, 50 to 70% of the cells were stained by polyclonal
antibodies for PRAD1/cyclin D1 [23]. (b) Using the samecarcinomas. In an immunohistochemical study, Zhang
et al found overexpression of PRAD1/cyclin D1 in 35 monoclonal antibodies for PRAD1/cyclin D1 that we
used, more than half of the nuclei were stained in mantleof 43 (81.4%) breast cancer cases, whereas amplification
of the gene was detected in 17% of these cases by South- cell lymphoma-proven gene abnormality of PRAD1/
cyclin D1 [16]. (c) In primary adenomas, we found aern blot analysis [18]. Overexpression of PRAD1/cyclin
D1 at the protein level was found in a large number distinctly divided expression of PRAD1/cyclin D1 by the
immunostaining. In this study, however, there was noof murine squamous cell carcinomas and papillomas,
although without demonstrating gene amplifications distinctly divided expression of PRAD1/cyclin D1 in sec-
ondary parathyroid hyperplasia, such as that seen in pri-[25]. It is suggested that mechanisms other than gene
rearrangements may be involved in the overexpression mary adenoma. A remarkable overexpression (LI of
more than 500) of PRAD1/cyclin D1 was not detectedof PRAD1/cyclin D1 protein in some tumors [25].
In this study, adenomas with remarkable overexpres- in nodular hyperplasia, including single nodular glands
histopathologically resembling primary adenoma. There-sion of PRAD1/cyclin D1 did not demonstrate greater
expression of Ki67 or pRB than did adenomas without fore, we suggest that at least the remarkable overexpres-
sion of PRAD1/cyclin D1 induced by PTH rearrangementsuch overexpression; we also could not find any differ-
ences in glandular weight or clinical manifestations in the does not play a major role in the development of parathy-
roid tumorigenesis in renal hyperparathyroidism. Never-two groups. Hence, it is suggested that some mechanism
suppresses the phosphorylation of pRB and transition theless, in a comparison of diffuse versus nodular hyper-
plasia, Ki67, PRAD1/cyclin D1, and pRB were found infrom G1 to S phase and inhibits transformation into a
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the latter to a significantly greater degree. However, netic abnormalities may have a stimulating influence on
PRAD1/cyclin D1 and thereby contribute to monoclonalwe did not find a significant correlation between the
expression of PRAD1/cyclin D1 and that of Ki67 in nod- parathyroid proliferation in some nodular hyperplasias.
ular hyperplasia as in primary adenoma. Based on these
results, it was clear that in some nodular hyperplasias ACKNOWLEDGMENTS
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